{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076843","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.876492+00:00","generated_at":"2026-05-15T23:40:51.292398+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tectonic Q4 net loss $19.2M; TX45 Phase 1b positive, TX2100 Phase 1a started","bullets":["Q4 net loss $19.2M (vs $12.4M YoY); R&D expenses $16.3M on advancing pipeline.","Cash and equivalents $253.8M as of Dec 31, 2025; expected cash runway into Q4 2028.","TX45 Phase 1b in PH-HFrEF showed 29.2% reduction in PCWP and 17.3% cardiac output improvement.","TX2100 Phase 1a in HHT randomized first subject Feb 2026; topline results expected Q4 2026.","François Nader appointed independent director effective April 1, 2026, to also serve as Board Chair."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076843","json":"https://secwatch.observer/filing/0001193125-26-076843.json","markdown":"https://secwatch.observer/filing/0001193125-26-076843.md","text":"https://secwatch.observer/filing/0001193125-26-076843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/0001193125-26-076843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/tecx-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:40:51.292398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}